TheraCryf

Executive Summary

TheraCryf plc is a UK-based clinical-stage therapeutics company advancing novel small molecules for behavioral brain disorders and oncology. Its lead neuropsychiatry programs target addiction and anxiety via an orexin-1 antagonist (TCRF-001) and fatigue via a dopamine transporter inhibitor (TCRF-002), both in Phase 1 development. The company also continues development of SFX-01, a legacy asset for glioblastoma, through a grant-funded collaboration. With a focus on high-unmet-need indications, TheraCryf aims to leverage its orexin-1 and dopamine transporter platforms to address significant market opportunities in neuropsychiatry. The company is private and has not disclosed its funding history or valuation, but its early-stage pipeline and grant-supported programs position it for potential value inflection pending clinical data readouts.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 data readout for orexin-1 antagonist (TCRF-001) in addiction/anxiety40% success
• Q2 2026Grant-funded preclinical or Phase 1 update for SFX-01 in glioblastoma60% success
• TBDPotential partnership or financing announcement30% success